期刊文献+

奥沙利铂加氟尿嘧啶治疗晚期食管癌的临床观察 被引量:3

Study of Oxaliplatin Combination with Fluorouracil in Treatment of Advanced Esophageal Carcinoma
下载PDF
导出
摘要 目的探讨奥沙利铂加氟尿嘧啶在晚期食管癌中的治疗价值。方法将我院收治的60例晚期食管癌患者按照治疗方法的不同分为观察组和对照组,对照组给予顺铂、亚叶酸钙联合氟尿嘧啶治疗,观察组给予奥沙利铂、亚叶酸钙联合氟尿嘧啶,比较两组患者的近期疗效、不良反应以及生活质量。结果观察组的总有效率为43.3%,对照组的为40.0%,无统计学意义(P>0.05)。两组的中位进展时间也无统计学意义(P>0.05)。但观察组在恶心、呕吐、腹泻等不良反应的发生率显著低于对照组,生存质量显著高于对照组(P<0.05)。结论奥沙利铂加氟尿嘧啶治疗晚期食管癌疗效满意,不良反应较少,是较为安全有效的化疗方案。 Objective To investigate the treatment value of oxaliplatin combination with 5-FU therapy in the treatment of advanced esophageal cancer. Methods 60 cases of advanced esophageal cancer patients were divided into the observation group and the control group according to the different treatment methods, while the control group was given cisplatin, leucovorin and fluorouracil in the treatment, the observation group was given oxaliplatin, leucovorin, fluorouracil; clinical efficacy, adverse reaction and life quality were compared between two groups. Results The total effective rate in the observation group was 43.3% that had no statistical significance with 40% in the control group(P〉0.05). The median time to progression between two groups have no statistical significance(P〉0.05). But the incidence of side reaction, nausea, vomiting, diarrhea in the observation group was significantly lower than that in the control group, the life quality was significantly higher than that in the control group(P〈0.05). Conclusion The curative effect of oxaliplatin combined with 5-FU in treatment of advanced esophageal cancer is less side reaction, chemotherapy; it is a safe and effective.
机构地区 江门市中心医院
出处 《中国医药指南》 2015年第4期27-28,共2页 Guide of China Medicine
关键词 奥沙利铂 氟尿嘧啶 晚期食管癌 不良反应 Oxaliplatin Fluorouracil Advanced esophageal cancer Adverse reaction
  • 相关文献

参考文献7

二级参考文献30

共引文献326

同被引文献30

  • 1Khouri C, Guiu B, Cercueil JP, et al. Rahitrexed and oxaliplatin hepatic arterial infusion for advanced colorectal cancer: a retrospective study [ J]. Anticancer Drugs, 2010,21 (6) : 656-658.
  • 2Shen J, Wang H, Wei J, et al. Thymidylate synthase mRNA levels in plasma and tumor as potential predictive biomarkers for raltitrexed sensitivity in gastric cancer [J]. Int J Cancer, 2012, 131 (6) : 938-945.
  • 3Liu Y, Wu W, Hong W, et al. Raltitrexed-based chemotherapy for advanced colorectal cancer [J]. Clin Res Hepatol Gastroenterol, 2014,38(2) : 219-225.
  • 4Ransom D, Wilson K, Fournier M, et al. Final results of Australasian Gastrointestinal Trials Group ARCTIC study: an audit ofraltitrexed for patients with cardiac toxicity induced by fluoropyrimidines [ J ]. Ann Oncol, 2014,25 ( 1 ) : 117-121.
  • 5Khouri C, Guiu B, Cereueil JP, et al. Raltitrexed and oxaliplatin hepatic arterial infusion for advanced colorectal cancer: a retrmpective study[J]. Ant;cancer Drugs; 2010,21 (6) :656-661.
  • 6Shen J,Wang H, Wei J, et al. Thymidylate synthase mRNA levels in plasma and tumor as potential predictive biomarkers for raltitrexed sensitivity in gastric caneer[J]. Int J Cancer, 2012,131(6) 938-945.
  • 7郑向东,鲍官明,王俊,等.雷替曲塞联合奥沙利铂二线治疗晚期消化道肿瘤疗效观察[J].中外健康文摘,2013,47(11):55-56.
  • 8Liu Y, Wu W, Hong W, et al. Raltitrexed-based chemotherapy for advanced coloreetal cancer [J]. Clin Res Hepatol Gastroenterol, 2014,38(2) : 219 - 225.
  • 9Ransom D, Wilson K, Fournier M, et al. Final results of Australasian Gastrointestinal Trials Group ARCTIC study:an audit ofraltitrexed for patients with cardiac toxicity induced by fluoropyrimidines[J]. Ann Oncol,2014,25(1):117-121.
  • 10王佳蕾,李进,秦叔逵,程颖,张清媛,刘天舒,杨春康,叶正宝,徐农,郑磊贞,胡春宏,张沂平,陶敏,于志坚,庄志祥.雷替曲塞或氟尿嘧啶/亚叶酸钙联合奥沙利铂治疗局部晚期或复发转移性结直肠癌的随机对照多中心Ⅲ期临床试验[J].临床肿瘤学杂志,2012,17(1):6-11. 被引量:122

引证文献3

二级引证文献20

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部